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Abstract 
Elongin A is a transcription elongation factor that increases the overall rate of mRNA 
chain elongation by RNA polymerase II. To gain more insight into the physiological 
functions of Elongin A, we generated Elongin A-deficient mice. Elongin A homozygous 
mutant (Elongin A-/-) embryos demonstrated a severely retarded development and died 
at between days 10.5 and 12.5 of gestation, most likely due to extensive apoptosis. 
Moreover, mouse embryonic fibroblasts (MEFs) derived from Elongin A-/- embryos 
exhibited not only increased apoptosis but also senescence-like growth defects 
accompanied by the activation of p38 MAPK and p53. Knockdown of Elongin A in 
MEFs by RNA interference also dramatically induced the senescent phenotype. A study 
using inhibitors of p38 MAPK and p53 and the generation of Elongin A-deficient mice 
with p53-null background suggests that both the p38 MAPK- and p53-pathways are 
responsible for the induction of senescence-like phenotypes, while additional signaling 
pathways appear to be involved in the mediation of apoptosis in Elongin A-/- cells. 
Taken together, our results suggest that Elongin A is required for the transcription of 
genes essential for early embryonic development and downregulation of its activity is 
tightly associated with cellular senescence. 
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interference; SA-β-gal, senescence-associated β-galactosidase; shRNA, short hairpin 
RNA 
 
 
Introduction 
Eukaryotic mRNA synthesis by RNA polymerase II (pol II) is regulated by the 
concerted action of a set of transcription factors that control the activity of pol II during 
the initiation and elongation stages of transcription. At least six general transcription 
factors have been identified in eukaryotic cells and found to promote the selective 
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binding of pol II to promoters and to support the basal level of transcription.1 In 
addition, a diverse collection of elongation factors that promote efficient elongation of 
transcripts by pol II in vitro have also been identified.2-4 These factors fall into two 
broad functional classes based on their ability to either reactivate arrested pol II or 
suppress the transient pausing of pol II. The first class is composed of members of the 
SII family.3,5 The second class comprises a collection of elongation factors, including 
TFIIF,6 Elongin,7,8 ELL9 and CSB,10 which increase the overall rate of mRNA chain 
elongation by decreasing the frequency and/or duration of transient pausing of pol II at 
sites along the DNA template. 
Elongin was identified as a heterotrimer composed of A, B and C subunits of ∼770, 
118, and 112 amino acids, respectively.7,8,11,12 Elongin A is the transcriptionally active 
subunit, whereas Elongins B and C are positive regulatory subunits that can form an 
isolable Elongin BC subcomplex.8,13,14 Although the functions of Elongin A in vivo 
remain largely unclear, Gerber et al. have recently reported that the Drosophila 
homologue of Elongin A (dEloA) colocalizes with pol II at sites of active transcription 
on polytene chromosomes, and it also plays a critical role in heat shock gene expression 
in vivo.15,16 Moreover, by the RNA interference (RNAi) knockdown of dEloA, they 
have also shown it to be an essential factor required for proper metamorphosis, although 
the relationship between the elongation activity and viability remains unclear.15 
To gain more insight into the physiological functions of Elongin A, we have 
generated Elongin A-deficient mice. Elongin A-/- embryos exhibited severe growth 
retardation and died at between days 10.5 and 12.5 of gestation, most likely due to 
excessive apoptosis. A cDNA microarray analysis of E10.5 embryos demonstrated an 
increased expression of hypoxia-response genes, including known transcriptional targets 
of p53, such as Ddit4 and Ndrg1, in Elongin A-/- embryos. Moreover, mouse embryonic 
fibroblasts (MEFs) derived from Elongin A-/- embryos displayed not only increased 
apoptosis but also the features of premature senescence, accompanied by the activation 
of p38 MAPK and p53. RNAi-mediated knockdown of Elongin A in MEFs also 
dramatically induced the senescent phenotype. A pharmacological study using 
SB203580 and pifithrin-α and generation of Elongin A-/- mice in p53-null background 
suggested that both the p38 MAPK- and p53-pathways are responsible for the induction 
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of senescence-like phenotypes, while additional signaling pathways, yet to be identified, 
appear to be involved in the mediation of apoptosis in Elongin A-/- cells. Taken together, 
our results demonstrate that Elongin A is an essential factor for viability, while also 
suggesting that it may regulate the transcription of genes essential for early embryonic 
development and that downregulation of its activity is strongly associated with cellular 
senescence. 
 
 
Results 
Elongin A-/- embryos die during embryogenesis 
The Elongin A mutant mice were generated by homologous recombination in CCE 
embryonic stem (ES) cells.17 Exons 8-10 of the Elongin A gene were replaced with a 
neomycin cassette in the gene-targeting vector (Figure 1a).18 The mutant ES cell clones 
with a disrupted Elongin A locus were used to obtain the germline chimeras that, in turn, 
were used to generate the heterozygous F1 mutant mice. The genotypes were 
determined using the polymerase chain reaction (PCR), and the loss of Elongin A 
expression was confirmed by reverse transcriptase (RT)-PCR (Figure 1b, c). The F1 
Elongin A+/- mice appeared to be normal. An analysis of live-born progeny obtained 
from crosses between F1 Elongin A+/- mice revealed the Elongin A mutation to be 
recessive embryonic lethal. To determine the timing of the death, the Elongin A 
genotypes the embryos at different stages of gestation were analyzed. As summarized in 
Table 1, Elongin A-/- embryos at E10.5 were found at a frequency that roughly matches 
the Mendelian distribution, thus indicating the lethality at the middle stage of embryonic 
development.  
In a previous study in adult mice, Elongin A mRNA was detected in all tissues 
examined.19 To examine whether Elongin A is expressed when such lethality occurs, we 
analyzed its expression at different developmental stages in wild-type embryos. A high 
level of Elongin A mRNA was detected in E4.5 embryos and was thereafter sustained 
throughout embryogenesis (Figure 1d), suggesting that Elongin A plays a critical role in 
embryonic development. 
 
Elongin A-/- embryos exhibit growth retardation and increased apoptosis 
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Gross inspection and fine histological examinations of live E10.5 Elongin A-/- embryos 
revealed a wide variety of severe developmental abnormalities. Overall, Elongin A-/- 
embryos were consistently smaller, and also severely more hypoplastic, than controls 
(Figure 2a-e). More specifically, Elongin A-/- embryos exhibited cardiac hypoplasia 
with abnormally thin ventricular walls, showing a minimum thickness of one cell layer, 
and dilated ventricles that presumably arose from the effects secondary to severe heart 
failure (Figure 2f, g). A poor development of the central nervous system and liver was 
also prominent. The thickness and cellularity of the spinal and cranial neuroepithelium 
were significantly reduced in Elongin A-/- embryos (Figure 2h, i). The livers of Elongin 
A-/- embryos were markedly decreased in size and composed of irregular trabeculae 
with fewer hepatocytes than in wild-type embryonic livers (Figure 2j, k). In addition to 
these defects, Elongin A-/- embryos were strikingly paler than the controls, but the 
presence of some nucleated red blood cells suggested that yolk sac hematopoiesis was 
only partially blocked (Figure 2a-c and data not shown). 
To clarify the cause of the developmental growth defect of Elongin A-/- embryos, we 
carried out both apoptosis and cell cycle analyses. A terminal dUTP nick end labeling 
(TUNEL) assay on E10.5 embryo sections revealed that massive numbers of 
TUNEL-positive cells were readily detectable in Elongin A-/- embryos, whereas very 
few cells were positive in wild-type embryos (Figure 2l, m). For the cell cycle analysis, 
we examined the incorporation of 5-bromo-2’-deoxyuridine (BrdU) and the expression 
of Ki67 nuclear protein in E10.5 embryos. The proportions of cells positive for each of 
these proliferation markers were similar in wild-type and Elongin A-/- embryos (Figure 
2n-u), suggesting that the rate of cell proliferation in vivo did not significantly decrease 
due to the loss of Elongin A. 
 
Elongin A-/- MEFs display apoptosis and senescence-like growth defect 
To rule out the possibility that the growth defect of Elongin A-/- embryos was due to 
extra-embryonic abnormalities, we examined the growth potential and apoptotic status 
of Elongin A-/- MEFs in vitro. Similar to the embryonic phenotype, MEFs prepared 
from Elongin A-/- embryos exhibited severe growth defects and a significant increase in 
the apoptotic population (Figure 3a, b). Therefore, these in vivo and in vitro data suggest 
that Elongin A-/- embryos have intrinsic growth defects and therefore undergo net cell 
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loss, at least in part, due to apoptotic cell death. 
Next, to test whether cell cycle regulation is affected in Elongin A-/- MEFs, BrdU 
incorporation assays were performed. In contrast to the findings in vivo, a moderate 
increase in the G0/G1 phase population accompanied by a concomitant decrease in the 
S-phase population was observed in Elongin A-/- MEFs (Figure 3c), suggesting that the 
number of cells actively cycling was decreased in Elongin A-/- MEFs. We also found 
that many Elongin A-/- MEFs displayed flattening and cytoplasmic enlargement, 
morphological features consistent with senescent cells, as early as after the first passage 
of culture (Figure 3d). We therefore checked the activity of senescence-associated 
β-galactosidase (SA-β-gal), a biochemical marker of senescence,20 in these cells. As 
shown in Figure 3e, approximately 30% of Elongin A-/- MEFs accumulated SA-β-gal, 
whereas very few of the controls displayed this marker, suggesting that the growth 
inhibition observed in Elongin A-/- MEFs was partly due to cellular senescence. 
 
Expression of hypoxia-response genes is increased in Elongin A-/- embryos 
To investigate whether the lack of Elongin A affects the expression levels of total 
mRNA, a dot blot analysis was performed. As shown in Figure 4a, the total mRNA 
levels in Elongin A-/- embryos were equivalent to those in the control embryos. 
Next, to examine the effects of Elongin A deletion on the expression levels of 
individual mRNAs, a cDNA microarray analysis comparing wild-type and Elongin A-/- 
embryos was performed. As shown in Figure 4b, of all genes analyzed only 0.4% 
showed increases of expression levels of more than 2-fold and only 0.3% showed 
decreases of more than 2-fold due to the lack of Elongin A. A differential expression of 
some of these genes was confirmed by semiquantitative RT-PCR. Most notably, a 
considerable proportion of the genes whose expression increased markedly in Elongin 
A-/- embryos were those known to be upregulated under hypoxic conditions. To 
investigate the mechanism of the induction of hypoxia-responsive genes in Elongin A-/- 
embryos, the expression level of hypoxia-inducible factor-1 (HIF-1) was analyzed. 
HIF-1 is a heterodimer that consists of the hypoxic response factor HIF-1α and the 
constitutively expressed HIF-1β.21,22 We therefore checked the expression of HIF-1α 
and its homologue HIF-2α by Western blotting. As shown in Figure 4c, however, the 
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protein levels of both HIF-1α and HIF-2α were not increased in the Elongin A-/- 
embryos, suggesting the possibility that other pathways, independent of HIF-1, may 
also play some role in the observed upregulation of the hypoxia-response genes. 
 
Activation of p53 and p38 MAPK in Elongin A-/- embryos and MEFs 
Those genes upregulated in the Elongin A-/- embryos, such as Ddit4 and Ndrg1,23,24 are 
also known to be direct transcriptional targets of p53, and their translational products 
are demonstrated to play an important role in p53-dependent apoptosis. In addition, 
hypoxia and the blockage of transcription elongation by agents such as UV light, 
camptothecin or actinomycin D have been shown to induce the phosphorylation of 
human p53 at Serine 15, resulting in the stabilization of the protein.25,26 We therefore 
checked whether this modification also occurs in Elongin A-/- embryos. As shown in 
Figure 5a, Elongin A-/- embryos indeed showed an increased phosphorylation of p53 at 
Ser18 (corresponding to Ser15 in human p53) in comparison to those of controls, thus 
suggesting that the p53 signaling pathway is also activated in Elongin A-/- embryos. 
Cellular senescence has been shown to be typically accompanied by the activation of 
p53 and pRb, along with an increased expression of cyclin-dependent kinase inhibitors, 
such as p16INK4a, p19ARF, and p21WAF1.27 To characterize the nature of the 
senescence-like growth defect of Elongin A-/- MEFs, we examined the expression of 
several key regulators of the cell cycle (Figure 5b). The expression levels of p16INK4a, 
p19ARF, and cyclin D1 were dramatically increased in Elongin A-/- MEFs. The induced 
expression of cyclin D1 is one of the characteristic features observed in senescent 
cells;28 therefore, the accumulation of cyclin D1 may have a rather inhibitory effect on 
cell growth. Modest increases in the levels of p53 and p21WAF1, and a significant 
decrease in hyperphosphorylated pRb, were also observed in Elongin A-/- MEFs. 
Although the precise molecular mechanisms remain unclear, the activation of the p38 
MAPK pathway has been reported to contribute to the induction of cellular 
senescence.29,30 To explore the possible involvement of p38 MAPK in the induction of 
senescence-like phenotypes in Elongin A-/- MEFs, we examined the levels of total and 
activated p38 MAPK in passage 2 MEFs and E10.5 whole embryos. The total amounts 
of p38 MAPK were essentially the same; however, a significant increase in the amount 
of phosphorylated p38 MAPK was observed in Elongin A-/- MEFs (Figure 5c, left 
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panel). Contrary to the results in MEFs, however, no increase in the phosphorylated p38 
MAPK was observed in the Elongin A-/- embryos (Figure 5c, right panel), thus 
suggesting that the onset of the senescence process in Elongin A-/- cells occurred during 
the ex vivo culture of MEFs, and not in utero. 
 
Senescence-like phenotype, but not apoptosis, in Elongin A-/- MEFs is rescued by 
the inhibition of both p53 and p38 MAPK 
To investigate whether the activated p53 and p38 MAPK really contribute to the 
induction of apoptosis and senescence-like phenotypes in Elongin A-/- MEFs, we 
cultured Elongin A-/- MEFs either with or without SB203580, which specifically 
inhibits the kinase activities of the α and β isoforms of p38 MAPK,31 and pifithrin-α, 
which specifically inhibits p53.32 We first examined the effect of these inhibitors on cell 
growth. Elongin A-/- MEFs treated with SB203580 showed a partial recovery, whereas 
those treated with either pifithrin-α or both inhibitors showed a complete recovery of 
cell growth (Figure 6a). We next examined the effect of these inhibitors on apoptosis. In 
contrast, the SB203580 treatment resulted in a partial reduction in the percentage of 
apoptotic cells in Elongin A-/- MEFs, but treatment with neither pifithrin-α nor both 
inhibitors had a significant effect on the apoptotic population (Figure 6b). We next 
examined the effect on the cell cycle status using BrdU incorporation assays. Elongin 
A-/- MEFs treated with SB203580 showed a moderate but significant increase in the 
proportion of actively cycling cells, whereas those treated with either pifithrin-α or both 
inhibitors demonstrated a complete recovery to a level even higher than that of 
untreated Elongin A+/- MEFs (Figure 6c). Finally, we examined the effect on the 
SA-β-gal activity. Treatment of Elongin A-/- MEFs with SB203580 resulted in a partial 
reduction of the percentage of cells positive for SA-β-gal activity. Combined treatment 
with both SB203580 and pifithrin-α resulted in complete inhibition, while that with 
pifithrin-α alone had no significant effect (Figure 6d). These results indicate that the 
activation of both p53 and p38 MAPK is responsible for mediating senescence-like 
growth defects, but not apoptosis, in Elongin A-/- MEFs. 
 
p53 mutation fails to rescue apoptosis and embryonic lethality in Elongin A-/- mice 
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In order to analyze the importance of p53 activation in apoptosis and lethality observed 
in Elongin A-/- embryos, we first generated Elongin A+/- p53+/- mice by crossing Elongin 
A+/- and p53+/- mice. We then interbred these mice and analyzed the genotypes of 
live-born progeny. Of the 117 mice analyzed, however, none were genotyped as 
Elongin A-/- p53-/- (Table 2). This indicates that the loss of p53 does not rescue the 
embryonic lethality caused by the Elongin A-/- mutation. Next, to assess the effect of 
p53 on apoptosis, we carried out cell death detection ELISA assays of E10.5 Elongin 
A-/- p53+/+ and Elongin A-/- p53-/- embryos. Consistent with the findings obtained with 
the TUNEL assays (Figure 2l, m), Elongin A-/- embryos showed significantly increased 
apoptosis compared with the wild-type embryos (Figure 7a). However, the extent of 
apoptosis in Elongin A-/- embryos was not decreased in the p53-/- background (Figure 
7b). In addition, Elongin A-/- p53+/+ and Elongin A-/- p53-/- embryos at E10.5 appeared to 
be morphologically undistinguishable (data not shown). These results indicate that a 
loss of p53 is not sufficient to overcome the apoptosis triggered by a deficiency of 
Elongin A. 
 
Induction of cellular senescence by RNAi-mediated knockdown of Elongin A 
To confirm the role of Elongin A in cellular senescence and apoptosis, we knocked 
down Elongin A in wild-type MEFs by RNAi-mediated gene silencing. Two 
independent sequences of Elongin A were used as targets of RNAi. As shown in Figure 
8a, MEFs transfected with plasmid vectors encoding either EloA1-1 or EloA1-2 short 
hairpin RNA (shRNA) specific for Elongin A mRNA exhibited a significant reduction 
in Elongin A mRNA levels compared with that apparent in MEFs transfected with a 
control vector. Expression of Elongin A shRNAs did not affect the expression of 
2’5’-oligoadenylate synthetase (OAS1), a classic interferon target gene that is induced 
>50-fold on activation of an interferon response.33 MEFs expressing Elongin A shRNAs 
exhibited a phenotypic change similar to those observed in MEFs derived from Elongin 
A-/- embryos, such as flattening, cytoplasmic enlargement and increase in SA-β-gal 
staining (Figure 8b, c), accompanied by increase in the amount of phosphorylated p38 
MAPK, and increased p16INK4a, p19ARF, p53, p21WAF1 and cyclin D1 expression (Figure 
8d). Contrary to Elongin A-/- mice, however, neither increased p53 Ser18 
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phosphorylation, activation of the hypoxia-response genes, nor induction of apoptosis 
was observed in MEFs expressing Elongin A shRNAs (Figure 8d-f). These results 
indicate that cellular senescence, but not apoptosis, can be induced in MEFs by 
RNAi-mediated knockdown of Elongin A. 
 
 
Discussion 
Numerous in vitro studies have demonstrated a requirement for the transcription 
elongation factors in transcriptional regulation; however, the functions of these factors 
in vivo have not been satisfactorily clarified.2-4 We therefore generated mice lacking one 
of these factors, Elongin A. Elongin A-/- embryos were severely retarded in 
development and died at between days 10.5 and 12.5 of gestation, most likely due to 
extensive apoptosis. Moreover, MEFs derived from Elongin A-/- embryos exhibited not 
only increased apoptosis but also senescence-like growth defects, accompanied by the 
activation of p38 MAPK and p53. Knockdown of Elongin A in MEFs by RNAi also 
dramatically induced the senescent phenotype. 
The expression of hypoxia-response genes was strongly increased in the Elongin A-/- 
embryos at E10.5 in comparison to the controls. What might be the mechanism for such 
upregulation? It is possible that an activated expression of the hypoxia-response genes 
as a physiological adaptation to hypoxia could terminate in wild-type embryos as the 
development of the cardiovascular system reaches a level that would allow the supply of 
sufficient oxygen to all tissues at this stage.21 On the other hand, it might continue in 
Elongin A-/- embryos because a developmental growth defect due to Elongin A 
deficiency leads to hypoplasia of the heart, which thus causes systemic hypoxia. 
Furthermore, the induction of the hypoxia-response gene expression is thought to be 
primarily mediated through the hypoxia-responsive transcription factor HIF-1;21,22 
however, the protein levels of neither HIF-1α nor HIF-2α, two key regulatory 
components of HIF-1, were observed to be increased in the Elongin A-/- embryos in 
comparison to the controls. It is noteworthy that p53 inhibits the hypoxia-induced 
expression of HIF-1α by promoting its MDM2-mediated ubiquitination and 
proteasomal degradation.34 It therefore seems possible that other pathways independent 
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of HIF-1 may also play some roles in the activation of hypoxia-response genes in 
Elongin A-/- embryos.22,35,36 In any case, the identification of the genes whose 
transcription is regulated by the action of Elongin A is thus considered to be essential to 
fully understand the mechanism of the activation for hypoxia-response genes in Elongin 
A-/- embryos. 
We have examined whether inhibitors of p53 and/or p38 MAPK are capable of 
rescuing the phenotypes of Elongin A-/- MEFs. Pifithrin-α rescued the growth defects of 
Elongin A-/- MEFs without restoring the flattened and enlarged morphology. On the 
other hand, SB203580 restored the morphology of Elongin A-/- MEFs to a level nearly 
equal to that of the control MEFs, even though it only partially rescued the growth 
defects. These findings suggest that, while p53 is essential for growth defects, p38 
MAPK plays a more dominant role in the senescence-associated changes of cell 
morphology in Elongin A-/- MEFs (Figure 9). Furthermore, as cellular senescence is 
irreversible, the finding that pretreatment with both SB203580 and pifithrin-α can 
rescue senescence-like phenotypes suggests that the senescence process in Elongin A-/- 
cells occurs during the ex vivo culture of MEFs, not in utero. Consistent with this 
assumption, neither the amount of phosphorylated p38 MAPK nor the proportion of 
cells positive for proliferation markers was significantly altered in the Elongin A-/- 
embryos in comparison to the controls at E10.5. 
In contrast to the senescence-like phenotypes, the inhibition of p53 neither by 
pifithrin-α nor by p53-null background rescued the accelerated apoptosis in Elongin A-/- 
MEFs or embryos, respectively. Since activation of hypoxia-response genes was 
observed in Elongin A-/- embryos and both the p53-dependent and -independent 
pathways have been demonstrated to be involved in the signaling of the hypoxic 
response,22,37,38 we assume that the hypoxic signaling pathway independent of p53 may 
thus play a more important causative role in the induction of apoptosis in Elongin A-/- 
mice (Figure 9). Consistent with our assumption, increased apoptosis was not observed 
in MEFs expressing Elongin A shRNAs, which were shown to be free of the 
upregulation of hypoxia-response genes. 
Finally, an expression analysis of mRNA demonstrated the total mRNA levels in 
Elongin A-/- embryos to be equivalent to those in the control embryos and that the 
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expression of only 0.3% of all genes analyzed were decreased more than 2-fold in the 
Elongin A-/- embryos in comparison with the wild-type embryos, suggesting that 
Elongin A regulates the transcription of only a small subset of genes. As Elongin A-/- 
mice showed lethality at the middle stage of embryonic development, Elongin A might 
be predicted to play a crucial role for the expression of at least one of those genes, 
whose expression must be precisely timed during development. The identification and 
functional analysis of Elongin A-responsive genes will help us to better understand how 
the loss of Elongin A contributes to embryonic lethality and the induction of apoptosis 
and cellular senescence. 
 
 
Materials and Methods 
Generation of Elongin A-deficient mice 
Elongin A mutant ES cell clones were generated as previously described18 and 
microinjected into blastocysts for the generation of chimeric mice. Chimeric males were 
crossed with C57BL/6 females, and agouti-colored offspring were analyzed for the 
germline transmission of the Elongin A mutation. Heterozygous animals were 
intercrossed to generate homozygous mutant animals. 
 
Generation of Elongin A-/- p53-/- mice 
Mice mutant for p53 were obtained from RIKEN BRC.39 Elongin A+/- mice were bred to 
p53 mutant mice, and the genotypes of the progeny were then determined by a PCR 
analysis. 
 
PCR genotyping 
Genomic DNA was isolated from mouse-tail biopsy samples and embryonic yolk sacs, 
and genotyping was performed using PCR. For Elongin A, a mixture of primers was 
used to detect wild-type and mutant alleles: A1, 5’-TCCTGAGGAGCTGGCCTATG-3’ 
(wild-type); A2, 5’-ACCGCCTGTGCTCTAGTAGC-3’ (mutant allele); and A3, 
5’-TTATCGCCGGGAGAATCTG-3’ (common). The conditions for PCR were 94°C 
for 30 s, 55°C for 30 s, and 72°C for 1 min, for 30 cycles. The amplified PCR products 
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of a 700-base pair (bp) fragment and a 600-bp fragment from wild-type and mutant 
alleles, respectively, were resolved on 2% agarose gels and stained with ethidium 
bromide. For p53, a set of primers, LCB614 5’-GTTATGCATCCATACAGTACA-3’ 
and LCB651 5’-CAGGATATCTTCTGGAGGAAG-3’, was used. The conditions were 
94°C for 30 s, 55°C for 30 s, and 72°C for 90 s, for 35 cycles. The products of a 400-bp 
fragment and a 1500-bp fragment from wild-type and mutant alleles, respectively, were 
resolved on 1% agarose gel and then were stained with ethidium bromide. 
For the paraffin sections of embryos, DNA was isolated using DEXPAT (TaKaRa) 
according to the manufacturer’s instructions, precipitated with ethanol and dissolved in 
0.1 × Tris-EDTA (TE) buffer. Genotyping was performed using nested PCR. The 
primers for the first PCR were: A1 (wild-type allele); C1, 
5’-AGTAGCCGTTATTAGTGGAGAGG-3’ (mutant allele); and C2, 
5’-CAGCAACAGGTCTCACCATGAG-3’ (common). The primers for the nested PCR 
were: C3, 5’-CCAGTACTAGCAGTGCCCAC-3’ (wild-type allele); A2 (mutant 
allele); and C4, 5’-GCCAGCCTGTCCTTGGCTCAG-3’ (common). The conditions for 
the first PCR were 94°C for 20 s, 61°C for 20 s, and 72°C for 20 s, for 35 cycles. The 
product of the first PCR was diluted 1:50 in 0.1 × TE buffer, and 2 μl was used for the 
nested PCR. The conditions for the nested PCR were 94°C for 20 s, 60°C for 20 s, and 
72°C for 20 s, for 35 cycles. The amplified PCR products of a 160-bp fragment and a 
120-bp fragment from wild-type and mutant alleles, respectively, were resolved on 3% 
agarose gel and then were visualized with UV light after staining with ethidium 
bromide. 
 
RT-PCR analysis 
Total RNA was isolated from either whole embryos or MEFs using an RNeasy Mini kit 
(Qiagen) according to the manufacturer’s protocol. First-strand cDNA was synthesized 
from 1 μg of total RNA, with an oligo-dT primer and MuLV reverse transcriptase 
(Applied Biosystems). One twentieth of each RT reaction product was used for PCR 
amplification. The primer sets used are B1 
(5’-TGGCCCAGTGGAAGAAGCTGGTTCCAG-3’) and B2 
(5’-GGCCTTTCTTCCTTAAAGTCTCGGTGACAGTG-3’) for Elongin A, TRIB3-F  
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(5’-GTTTCCTGCAGGAAGAAACCG-3’) and TRIB3-R 
(5’-GTGCCACGGCACTAGCCATC-3’) for Tribbles 3 (Trib3), STC2-F 
(5’-CAGTTTGTGACCCTGGCTTTG-3’) and STC2-R 
(5’-CACAATCACACCGACGTTCTC-3’) for Stanniocalcin 2 (Stc2), DDIT4-F 
(5’-CTTCTGTGCGCCTTCATTC-3’) and DDIT4-R 
(5’-CTCAGGTGGCTATCGTCAGT-3’) for DNA-damage-inducible transcript 4 
(Ddit4), NDRG1-F (5’-ACAACCCCCTCTTCAACTCTG-3’) and NDRG1-R 
(5’-CATTCCACCACAGCATCCACG-3’) for N-myc down-regulated gene 1 (Ndrg1), 
NIP3-F (5’-CTGGGTAGAACTGCACTTCAG-3’) and NIP3-R 
(5’-GCGCTTCGGGTGTTTAAAAAGG-3’) for Bcl-2-interacting protein 1 (Bnip3), 
HIG1-F (5’-GTCAACCAACACAGACCTTTCTC-3’) and HIG1-R 
(5’-CTAAGGCTTAGGCTTAGGGTTG-3’) for Hypoxia-induced gene 1 (Hig1), 
VEGFa-F (5’-CTTGGGTGCACTGGACCCTG-3’) and VEGFa-R 
(5’-GGTTTGATCCGCATGATCTGC-3’) for Vascular endothelial growth factor A 
(Vegfa), p21-F (5’-AATCCTGGTGATGTCCGACC-3’) and p21-R 
(5’-AAAGTTCCACCGTTCTCGG-3’) for p21WAF1, and OAS1-F 
(5’-TGTGCGAGGTTCAGCATGAG-3’) and OAS1-R 
(5’-ACTGTCCAGTAGATTTGAAG-3’) for OAS1, and mGA1 
(5’-CTGCCATTTGCAGTGGCAAAG-3’) and mGA2 
(5’-TGGTATTCAAGAGAGTAGGGA-3’) for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). All cDNAs were amplified in the quantitative ranges: 20 
cycles for Ddit4, Bnip3, and Hig1, 25 cycles for Trib3, Stc2, Ndrg1, and Vegfa, 30 
cycles for Elongin A and GAPDH, and 35 cycles for p21 and OAS1. The amplified 
PCR products were resolved on 1-2% agarose gel and then were visualized with UV 
light after staining with ethidium bromide. 
 
Northern blot analysis 
Mouse Embryo Full Stage Blot (Seegene), containing 20 μg of total RNA per sample, 
was hybridized using ExpressHyb solution (Clontech) under stringent conditions as 
recommended by the manufacturer. The mouse Elongin A probe contained the sequence 
encoding amino acids 97-468, and the blot was stripped and reprobed using GAPDH 
cDNA. 
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Dot blot analysis 
To determine the total mRNA level in the E10.5 embryos with different Elongin A 
genotypes, 1 μg of heat-denatured RNA (70°C for 3 min) was added to 100 ml of 1 M 
ammonium acetate and blotted onto a nylon filter (Hybond-N+, Amersham Biosciences) 
with a dot blotter manifold (Sanplatec). The filter was air-dried and prehybridized 
overnight at 37°C in 4 × SSC (1 × SSC is 0.15 M NaCl, 0.015 M Na-citrate), 0.2% 
Ficoll, 0.2% polyvinylpyrrolidone, 0.5% sodium dodecyl sulfate (SDS), and 200 mg/ml 
denatured salmon sperm DNA, followed by hybridization at 37°C with 8 mCi/ml of 
32P-labeled poly(dT) in the prehybridization buffer for 12-20 h. The filter was washed at 
37°C for 15 min with the prehybridization buffer and then three times at room 
temperature for 20 min each time in 1 × SSC and 0.1% SDS. 
 
Microarray analysis 
Total RNA was isolated from Elongin A+/+ and Elongin A-/- E10.5 embryos according to 
the manufacturer’s protocol using an RNeasy Mini kit (Qiagen). Aliquots (1 μg) of total 
RNA were labeled using the Agilent Linear Amplification/Labeling kit (Agilent 
Technologies) according to the manufacturer’s instructions. After checking the labeling 
efficiency, 1-μg aliquots of Cy3-labeled Elongin A+/+ cRNA and Cy5-labeled Elongin 
A-/- cRNA were mixed, then hybridized to an Agilent Whole Mouse Oligo Microarray 
using the manufacturer’s hybridization protocol. After the washing step, the microarray 
slide was analyzed with an Agilent Microarray scanner and software (scanner model 
G2505B, software G2565BA). A data analysis was performed using Agilent Feature 
Extraction software (Version A.6.1.1). 
 
Histological analysis 
Pregnant mice were killed at E10.5, and whole uteri were fixed in 4% paraformaldehyde 
for several hours, then in 20% neutral buffered formalin overnight. After fixation, the 
embryos were carefully dissected, embedded in paraffin, sectioned at 5 μm, and stained 
with hematoxylin and eosin.  
A TUNEL assay was performed on paraffin sections of E10.5 embryos using the 
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ApopTag Plus Peroxidase In situ Apoptosis Detection kit (Serologicals) according to 
the manufacturer’s instructions. 
Immunostaining with anti-Ki67 nuclear antigen (YLEM) was performed following 
the manufacturer’s instructions. An Alexa 488-conjugated anti-rabbit antibody 
(Molecular Probes) was used as the secondary antibody, and slides were also stained 
with DAPI to visualize all nuclei. 
For BrdU experiments, pregnant mice at E10.5 were injected intraperitoneally with 
BrdU (Sigma) in phosphate-buffered saline (PBS) at a dose of 100 μg/g of body weight. 
The mice were killed 2 h after the injection, and the embryos were fixed with 4% 
paraformaldehyde. The fixed sections were denatured by incubation in 1 N HCl at 65°C 
for 30 min and then were stained with anti-BrdU antibody (Roche). 
 
Mouse embryonic fibroblast assays 
MEFs were prepared from either E10.5 or E13.5 embryos. Fetal tissue samples were 
rinsed in PBS and then were mechanically dissociated in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (FBS). The cells were then plated out 
on 6-well plates. These cells were considered to be passage 1 MEFs. 
For growth curves, 2.5 × 104 cells were plated in triplicate into 12-well plates. At 
various time points, the cells were trypsinized and counted using a hemocytometer. 
For the quantitative detection of apoptotic cells, both adherent and floating cells were 
harvested and stained with annexin V-fluorescein isothiocyanate (FITC) and propidium 
iodide (PI) using the Annexin V-FITC Apoptosis Detection kit (BioVision) according to 
the manufacturer’s instructions. The stained cells were analyzed with a FACSCalibur 
(Becton Dickinson) using the CELL Quest software package (BD Biosciences). 
For the cell cycle analysis, MEFs grown in DMEM with 10% FBS were 
metabolically labeled with 10 μM BrdU for 48 h. The cells were harvested and fixed in 
70% ethanol at 4°C overnight. The cells were then treated with 2 N HCl and 0.5% 
Triton X-100 for 30 min at room temperature, followed by neutralization with 0.1 M 
Na2B4O7 (pH 8.5) and subsequent incubation with FITC-conjugated anti-BrdU antibody 
(PROGEN) for 1 h at room temperature. Finally, the cells were washed with PBS and 
0.5% Tween 20, resuspended in PBS containing 5 μg/ml PI, and analyzed with a 
 17
FACSCalibur (Becton Dickinson) using the CELL Quest software package (BD 
Biosciences). 
For the pharmacological inhibition of p38 MAPK and p53 activity, SB203580 
(BIOMOL) and pifithrin-α (Calbiochem), respectively, were dissolved in 
dimethylsulfoxide (DMSO) and added to the cultures immediately after the isolation of 
MEFs. 
 
Senescence-associated β-galactosidase assay 
SA-β-gal activity at pH 6.0 was measured using a Senescence β-galactosidase Staining 
kit (Cell Signaling) according to the manufacturer’s instructions. 
 
Quantitative analysis of apoptosis in whole embryos 
For the quantitative analysis and to determine the cytoplasmic histone-associated DNA 
fragments, which are indicative of on-going apoptosis, the Cell Death Detection 
ELISAPLUS (Roche Applied Science) was used according to the manufacturer’s 
instructions. 
 
Western blot analysis 
Whole-cell extracts of E10.5 embryos or MEFs were prepared in lysis buffer [50 mM 
Tris-HCl (pH 7.0), 2% SDS, 10% glycerol, 50 mM NaF and 1 mM Na3VO4] containing 
the Complete Protease Inhibitor Cocktail (Roche Applied Science). The protein 
concentration was determined by using the Bradford assay, and 75 μg of each extract 
was fractionated by SDS-polyacrylamide gel electrophoresis and transferred to a 
polyvinylidene difluoride membrane (Millipore). The following primary antibodies 
were used: HIF-1α (H1α67, Novus Biologicals), HIF-2α (Novus Biologicals), Rb 
(C-15, Santa Cruz), p53 (FL-393 from Santa Cruz and CM5 from Novocastra), 
phospho-p53 (human Ser15, Cell Signaling), p16INK4a (M-156, Santa Cruz), p19ARF 
(Neo Markers), p21WAF1 (C-19, Santa Cruz), cyclin D1 (DCS-6, MBL), p38 (Cell 
Signaling), phospho-p38 (Thr180/Tyr182, Cell Signaling), and α-tubulin (DM1A, 
Sigma). Horseradish peroxidase-conjugated donkey anti-rabbit or sheep anti-mouse 
antibodies (Amersham) were used as secondary antibodies. Detection was performed 
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using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). 
 
RNA interference 
DNA corresponding to an shRNA sequence was subcloned into the SacI and KpnI sites 
of piGENE-tRNA-Neo vector (iGENE Therapeutics), which expresses tRNA-shRNA 
under the control of the human tRNAVal promoter. The DNA for the shRNA encodes a 
30-nucleotide hairpin sequence specific to the mRNA target, with a loop sequence 
(AAAACTCGAGAAAA) separating the two complementary domains. The hairpin 
sequences specific for mouse Elongin A mRNA correspond to nucleotides 1111 to 1140 
(EloA1-1) and 2077 to 2106 (EloA1-2) of the coding region. E13.5 MEFs were 
transfected with these vectors using FuGENE 6 (Roche) according to the 
manufacturer’s protocol. After 24 h, the transfected cells were selected in medium 
containing 400 μg/ml G418 (Sigma) for 4 to 6 days and were used for experiments. 
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Titles and legends to figures 
 
Figure 1  Generation of Elongin A-deficient mice. (a) A diagram showing the 
genomic organization of the Elongin A gene, the targeting vector, and the targeted allele 
after homologous recombination. The coding exons, depicted by closed boxes, are 
numbered 1-11. A1, A2, and A3, or B1 and B2, indicate the primers used for PCR 
genotyping or RT-PCR analysis, respectively. TK, thymidine kinase cassette; NEO, 
neomycin resistance cassette. (b) A representative PCR-based genotype analysis of 
embryos from Elongin A+/- intercrosses. PCR products from the wild-type (WT) and 
mutant alleles are indicated. (c) RT-PCR analysis of Elongin A (upper panel) or the 
GAPDH gene (lower panel) in Elongin A+/+, Elongin A+/-, and Elongin A-/- MEFs. (d) 
Expression of Elongin A in mouse embryos. Total RNA, isolated from embryos at 
various indicated developmental stages, was subjected to a Northern blot analysis with 
cDNA probes. 
 
Figure 2  Morphology and histology of E10.5 embryos with different Elongin A 
genotypes. (a, b, c) Gross morphology of Elongin A+/+ (a), Elongin A+/- (b), and Elongin 
A-/- (c) embryos. Note the small size and paleness of Elongin A-/- embryos. (d, e) 
Overview of sagittal sections of Elongin A+/+ (d) and Elongin A-/- (e) embryos. Scale 
bars, 1 mm. (f, g) Heart sections from Elongin A+/+ (f) and Elongin A-/- (g) embryos. 
Magnification, 100×. Note the cardiac hypoplasia with significantly thinner ventricular 
walls (arrow) in the Elongin A-/- embryo. (h, i) Forebrain sections from Elongin A+/+ (h) 
and Elongin A-/- (i) embryos. Magnification, 100×. Note the reduced thickness and 
cellularity of the cranial neuroepithelium in the Elongin A-/- embryo (arrow). (j, k) Liver 
sections from Elongin A+/+ (j) and Elongin A-/- (k) embryos. Magnification, 200×. Note 
the smaller liver and irregular trabecular structure in the Elongin A-/- embryo (arrow). (l, 
m) A TUNEL analysis of sagittal sections from Elongin A+/+ (l) and Elongin A-/- (m) 
embryos. Magnification, 400×. Large numbers of apoptotic cells are detected in the 
Elongin A-/- embryo. (n-s) Sagittal sections of Elongin A+/+ (n, o, p) and Elongin A-/- (q, 
r, s) embryos at E10.5 were stained with anti-Ki67 antibody to visualize proliferating 
cells (n, q), with DAPI to visualize the nuclei (o, r), and with both anti-Ki67 and DAPI 
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(p, s). Scale bar, 10 μm. (t, u) Incorporation of BrdU in Elongin A+/+ (t) and Elongin A-/- 
(u) embryos at E10.5. Scale bars, 10 μm.  
 
Figure 3  Increased apoptosis and senescence-like growth defect in Elongin A-/- 
MEFs. (a) Growth curves for Elongin A+/+, Elongin A+/-, and Elongin A-/- MEF cultures 
at passage 2. The cultures were harvested at the indicated time points, and the total 
number of cells was determined and normalized to the number of cells at day 1 (24 h 
after plating). The average for three independently derived MEF cultures of each 
genotype analyzed in duplicate is shown. (b) An analysis of apoptosis in Elongin A+/+, 
Elongin A+/-, and Elongin A-/- MEFs. The population of apoptotic cells was determined 
by annexin V-FITC and PI staining. Typical annexin V/PI FACS profiles of MEFs are 
shown. The percentage of cells in each fraction is shown below. (c) An analysis of the 
percentage of actively cycling cells in Elongin A+/- and Elongin A-/- MEFs. MEFs at 
passage 2 were continuously labeled with BrdU for 48 h and then stained with 
anti-BrdU to detect DNA synthesis (vertical axis) and with PI to detect total DNA 
(horizontal axis). The numerical data are the averages of measurements with three 
independently derived MEF cultures of each genotype. FACS profiles for a typical 
experiment are shown as an example. (d) Morphology of MEFs at passage 2. Elongin 
A-/- MEFs showed a flattened and enlarged morphology compared with the Elongin A+/+ 
MEFs. (e) SA-β-gal staining of MEFs at passage 2 (left panel) and percentages of cells 
positive for this staining (right panel). Elongin A-/- MEFs showed an increase in the 
number of SA-β-gal-positive cells. *P>0.05. **P<0.05. 
 
Figure 4  Increased expression of hypoxia-responsive genes in Elongin A-/- embryos at 
E10.5. (a) Comparison of total mRNA levels in Elongin A+/+, Elongin A+/-, and Elongin 
A-/- embryos at E10.5. (b) Identification of genes differentially expressed in Elongin 
A+/+ and Elongin A-/- whole embryos using a microarray analysis. Genes upregulated 
more than 2-fold in Elongin A-/- embryos are listed (left panel) and the results were 
confirmed by RT-PCR assays (right panel). The asterisks indicate hypoxia-response 
genes. (c) A Western blot analysis of HIF-1α and HIF-2α from lysates of Elongin A+/+, 
Elongin A+/-, and Elongin A-/- whole embryos. α-Tubulin was used as a loading control. 
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Figure 5  The activation of p53 and p38 MAPK in Elongin A-/- embryos and MEFs. 
(a) Western blot analysis of p53 phosphorylation at Ser18, from lysates of Elongin A+/+, 
Elongin A+/- and Elongin A-/- whole embryos. α-Tubulin was used as a loading control. 
(b) An expression analysis of various cell cycle regulatory proteins. Elongin A+/+, 
Elongin A+/-, and Elongin A-/- MEFs at passage 2 were analyzed by Western blotting 
using the indicated antibody; α-tubulin was used as a loading control. (c) Western blot 
analysis of p38 MAPK (p38, total p38; and P-p38, phosphorylated p38) from lysates of 
Elongin A+/+, Elongin A+/-, and Elongin A-/- MEFs at passage 2 (left panel) and whole 
embryos (right panel); α-tubulin was used as a loading control. 
 
Figure 6  Effects of p53 and p38 MAPK inhibitors on apoptosis and senescence-like 
growth defect in Elongin A-/- MEFs. (a) Representative growth curves documenting the 
effects of pifithrin-α (PFT) and SB203580 (SB) on the growth of Elongin A+/- and 
Elongin A-/- MEFs at passage 2. (b) Effects of PFT and SB on the percentage of 
apoptotic cells in Elongin A+/- and Elongin A-/- MEFs. *P<0.05. (c) Effects of PFT and 
SB on the percentage of actively cycling cells in Elongin A+/- and Elongin A-/- MEFs. 
*P<0.05. **P<0.005. (d) Effects of PFT and SB on the SA-β-gal staining (upper panel) 
and percentages of cells positive for this staining (lower panel) in Elongin A+/- and 
Elongin A-/- MEFs at passage 2. *P<0.05. **P<0.005. 
 
Figure 7  Effect of p53 mutation on the level of apoptosis in Elongin A-/- embryos. (a) 
A quantitative analysis of the cytoplasmic histone-associated DNA fragments in 
Elongin A+/+ and Elongin A-/- embryos at E10.5. (b) Effect of p53 mutation on the level 
of apoptosis in Elongin A+/+ and Elongin A-/- embryos at E10.5. The level of apoptosis 
in embryos was determined by ELISA quantification of cytoplasmic histone-associated 
DNA fragments. 
 
Figure 8  Induction of cellular senescence in MEFs by RNAi knockdown of Elongin 
A. (a) RT-PCR analysis of Elongin A (upper panel), OAS1 (middle panel), or the 
GAPDH gene (lower panel) in MEFs 7 days after the transfection of control or Elongin 
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A shRNA (EloA1-1 or EloA1-2) vector. (b) Morphology of MEFs transfected with 
control or Elongin A shRNA vector at day 7. (c) SA-β-gal staining of MEFs transfected 
with control or Elongin A shRNA vector at day 7 (upper panel), and percentages of 
cells positive for this staining (lower panel). (d) Phosphorylation status of p38 MAPK 
and p53 Ser18, and expression of various cell cycle regulatory proteins were analyzed 
by Western blotting using lysates of MEFs transfected with control or Elongin A 
shRNA vector at day 7. α-Tubulin was used as a loading control. (e) RT-PCR analysis 
of various hypoxia-response genes in MEFs transfected with control or Elongin A 
shRNA vector at day 7. (f) A quantitative analysis of the cytoplasmic histone-associated 
DNA fragments in MEFs transfected with control or Elongin A shRNA vector at day 5. 
 
Figure 9  A working model summarizing how Elongin A inactivation results in 
cellular senescence, apoptosis, and embryonic lethality. 












